{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/INDV/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-10T22:28:24.231Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6676,"canonical_name":"Indivior Pharmaceuticals, Inc.","cik":"0001625297","uei":null,"lei":null,"duns":null,"ticker":"INDV"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":32},"count":32,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"424B3","title":"424B3 — Indivior Pharmaceuticals, Inc. — 2026-09-11","url_slug":"/sec/cik-0001625297/424b3/0001104659-26-107070","accession_number":"0001104659-26-107070","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-07-13","url_slug":"/sec/cik-0001625297/4/0002014639-26-000011","accession_number":"0002014639-26-000011","importance":30},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Heidbreder Christian","title":"Chief Scientific Officer","shares":18586,"price_per_share":41.14,"usd_value":764628,"security_title":"Common Stock","importance":35.76462804},{"ts":"2026-07-10","kind":"sec.filing","form_type":"144","title":"144 — Indivior Pharmaceuticals, Inc. — 2026-07-10","url_slug":"/sec/cik-0001625297/144/0001959173-26-005188","accession_number":"0001959173-26-005188","importance":30},{"ts":"2026-06-22","kind":"sec.insider.f","reporter":"Ciaffoni Joseph","title":"Chief Executive Officer","shares":612549,"price_per_share":38.32,"usd_value":23472878,"security_title":"Common Stock","importance":38.472877679999996},{"ts":"2026-06-22","kind":"sec.insider.m","reporter":"Ciaffoni Joseph","title":"Chief Executive Officer","shares":1266903,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-06-12","url_slug":"/sec/cik-0001625297/4/0002014639-26-000009","accession_number":"0002014639-26-000009","importance":30},{"ts":"2026-06-11","kind":"sec.form144","reporter":"Heidbreder Christian","title":"Officer","shares":18586,"usd_value":707383,"security_title":"Common","approx_sale_date":"2026-06-11","accession_number":"0001959173-26-004549","importance":40.141476632},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Heidbreder Christian","title":"Chief Scientific Officer","shares":18586,"price_per_share":38.06,"usd_value":707383,"security_title":"Common Stock","importance":35.70738316},{"ts":"2026-06-11","kind":"sec.filing","form_type":"144","title":"144 — Indivior Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001625297/144/0001959173-26-004549","accession_number":"0001959173-26-004549","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-06-10","url_slug":"/sec/cik-0001625297/4/0002014866-26-000011","accession_number":"0002014866-26-000011","importance":30},{"ts":"2026-06-08","kind":"sec.form144","reporter":"Preblick Ryan","title":"Officer","shares":36000,"usd_value":1357200,"security_title":"Common","approx_sale_date":"2026-06-08","accession_number":"0001959173-26-004434","importance":40.27144},{"ts":"2026-06-08","kind":"sec.form144","reporter":"Preblick Ryan","title":"Officer","shares":36000,"usd_value":1357200,"security_title":"Common","approx_sale_date":"2026-06-08","accession_number":"0001959173-26-004422","importance":40.27144},{"ts":"2026-06-08","kind":"sec.insider.s","reporter":"Preblick Ryan","title":"Chief Financial Officer","shares":36000,"price_per_share":37.7,"usd_value":1357200,"security_title":"Common Stock","importance":36.3572},{"ts":"2026-06-08","kind":"sec.filing","form_type":"144","title":"144 — Indivior Pharmaceuticals, Inc. — 2026-06-08","url_slug":"/sec/cik-0001625297/144/0001959173-26-004422","accession_number":"0001959173-26-004422","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"144/A","title":"144/A — Indivior Pharmaceuticals, Inc. — 2026-06-08","url_slug":"/sec/cik-0001625297/144-a/0001959173-26-004434","accession_number":"0001959173-26-004434","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Indivior Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001625297/8-k/0001625297-26-000024","accession_number":"0001625297-26-000024","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Indivior Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001625297/schedule-13g-a/0001013594-26-000584","accession_number":"0001013594-26-000584","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001625297/4/0001715258-26-000007","accession_number":"0001715258-26-000007","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001625297/4/0001789507-26-000008","accession_number":"0001789507-26-000008","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001625297/4/0001827169-26-000013","accession_number":"0001827169-26-000013","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — Indivior Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001625297/4/0002014900-26-000009","accession_number":"0002014900-26-000009","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — FULLER & THALER ASSET MANAGEMENT, INC. — 2026-05-13","url_slug":"/sec/cik-0001082327/schedule-13g-a/0001941040-26-000335","accession_number":"0001941040-26-000335","importance":30},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"NINIVAGGI DANIEL A","title":null,"shares":6518,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Kingsley Stuart A","title":null,"shares":6518,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Stejbach Mark","title":null,"shares":6518,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Wheadon David E.","title":null,"shares":10430,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Thompson Juliet","title":null,"shares":6518,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Humphreys Keith","title":null,"shares":6518,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Ryan Barbara","title":null,"shares":6518,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-12","kind":"sec.insider.f","reporter":"Thompson Juliet","title":null,"shares":1117,"price_per_share":38.28,"usd_value":42759,"security_title":"Common Stock","importance":15.04275876},{"ts":"2026-04-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Indivior Pharmaceuticals, Inc. — 2026-04-27","url_slug":"/sec/cik-0001625297/schedule-13g/0002100119-26-000006","accession_number":"0002100119-26-000006","importance":55}]}